Methods and computing devices for quantifying the degree of chronic inflammation

Abstract

This invention provides a method for quantifying the degree of chronic inflammation, comprising: obtaining multiple assessment parameters relating to at least one of symptoms and medication status of an item to be assessed in a person to be assessed; obtaining multiple corresponding inflammation scores based on the assessment parameters; determining whether at least one of multiple weighting conditions is triggered based on the assessment parameters; and when it is determined that the at least one weighting condition is triggered, performing a weighting process on the obtained inflammation scores to obtain a quantitative score indicating the degree of inflammation of the item to be assessed in the person to be assessed. This invention also provides a computing device for performing the above method.

Description

Technical Field

[0001] The present invention relates to a method for quantifying the degree of inflammation and a computing device thereof, and in particular to a method for simultaneously incorporating the chronic inflammation conditions of different parts into the assessment of the overall degree of inflammation and quantifying it and a computing device thereof. Prior Art

[0002] Inflammation is a protective response initiated by the immune system to combat external stress or pathogen invasion. When inflammation persists for too long, it can lead to excessive accumulation of reactive oxygen species and free radicals in tissues, causing oxidative stress and damage, ultimately leading to chronic inflammation. Chronic inflammation can occur in various organs and tissues throughout the body, including but not limited to eczema, urticaria, allergic rhinitis, allergic conjunctivitis, asthma, sequelae of COVID-19, autoimmune diseases, and tumors.

[0003] Currently, the diagnosis of chronic inflammation in clinical practice is primarily performed by physicians from different specialties, each diagnosing and treating each case independently based on the specific location and type of inflammation. However, this approach overlooks the potential connections between these different inflammatory symptoms, preventing a comprehensive assessment to identify appropriate treatment strategies.

[0004] To the best of the applicant's knowledge, no literature or prior patents have ever disclosed a method for simultaneously incorporating chronic inflammation at different sites into the assessment of the overall inflammation level and quantifying it. Summary of the Invention

[0005] Therefore, the purpose of the present invention is to provide a method for simultaneously incorporating the chronic inflammation conditions of different parts into the assessment of the overall inflammation level and quantifying it.

[0006] Therefore, the present invention provides a method for quantifying the degree of chronic inflammation, which is suitable for quantifying the degree of inflammation of a subject to be evaluated and is executed by a computing device. The method comprises the following steps: (a) obtaining a plurality of assessment parameters related to at least one of the symptoms and medication status of the subject to be assessed; (b) obtaining a plurality of corresponding inflammation scores according to the evaluation parameters; (c) determining whether at least one of the plurality of weighted conditions is triggered based on the evaluation parameters; and (d) When it is determined that the at least one weighting condition is triggered, a weighting process is performed on the obtained inflammation score to obtain a quantitative score indicating the degree of inflammation of the item to be evaluated of the person to be evaluated.

[0007] Another object of the present invention is to provide a computing device that simultaneously incorporates the chronic inflammation conditions of different parts of the body into the assessment of the overall inflammation level and quantifies it.

[0008] Therefore, the present invention provides a computing device for quantifying the degree of chronic inflammation, which includes a storage module and a processing module electrically connected to the storage module.

[0009] The storage module stores a plurality of weighted conditions of a plurality of evaluation parameters related to chronic inflammatory symptoms and medication status.

[0010] The processing module is used to obtain multiple assessment parameters related to at least one of the symptoms and medication status of the subject to be assessed, obtain multiple corresponding inflammation scores based on the assessment parameters, and determine whether at least one of multiple weighted conditions is triggered based on the assessment parameters. When it is determined that the at least one weighted condition is triggered, a weighted processing is performed on the obtained inflammation score to obtain a quantitative score indicating the degree of inflammation of the subject to be assessed.

[0011] The present invention is effective in that a computing device obtains multiple corresponding inflammation scores based on multiple assessment parameters related to the symptoms and medication status of the person to be assessed, and performs weighted processing when a weighted triggering condition is determined, thereby obtaining a quantitative score indicating the degree of inflammation in the person to be assessed, thereby effectively assessing the overall degree of inflammation in different parts of the chronic inflammation suffered by the person to be assessed. Simple diagram description

[0012] Other features and effects of the present invention will be clearly presented in the embodiments with reference to the accompanying drawings, in which: Figure 1 is a block diagram illustrating a computing device for implementing an embodiment of a method of quantifying the degree of chronic inflammation of the present invention; FIG2 is a flow chart illustrating an embodiment of a method for quantifying the degree of chronic inflammation according to the present invention; and FIG3 is a flow chart illustrating an embodiment of a method for quantifying the degree of chronic inflammation according to the present invention. Implementation Method

[0013] Referring to FIG. 1 , an embodiment of a method for quantifying the degree of chronic inflammation according to the present invention is applicable to quantifying the degree of inflammation of a subject's assessed item and is executed by a computing device 1 . The computing device 1 includes a storage module 11 and a processing module 12 electrically connected to the storage module 11 .

[0014] The storage module 11 stores a plurality of weighted conditions of a plurality of evaluation parameters related to chronic inflammatory symptoms and medication status.

[0015] The processing module 12 is used to obtain multiple assessment parameters related to at least one of the symptoms and medication status of the subject to be assessed, obtain multiple corresponding inflammation scores based on the assessment parameters, and determine whether at least one of multiple weighted conditions is triggered based on the assessment parameters. When it is determined that the at least one weighted condition is triggered, a weighted processing is performed on the obtained inflammation score to obtain a quantitative score indicating the degree of inflammation of the subject to be assessed.

[0016] The following will illustrate the operation details of the computing device 1 through an embodiment of the method for quantifying the degree of chronic inflammation of the present invention.

[0017] 2 and 3 , the method for quantifying the degree of chronic inflammation includes steps 21 to 25 and 31 to 33 .

[0018] In step 21 , the processing module 12 of the computing device 1 obtains a plurality of evaluation parameters related to at least one of the symptoms and medication status of a first evaluation item of a person to be evaluated.

[0019] According to the present invention, the evaluation parameters include at least one of a plurality of symptom onset parameters related to the symptom onset type of the subject to be evaluated, a plurality of time parameters related to the symptom onset time of the subject to be evaluated, and a plurality of medication parameters related to the medication status of the subject to be evaluated.

[0020] Preferably, the symptom onset parameter includes at least one of a symptom type parameter indicating the severity of the symptom onset type (including but not limited to the appearance of proliferative tissue: 4 points, the appearance of tissue redness or rash: 2 points, and none: 0 points), a symptom range parameter indicating the severity of the scope of the symptom onset site (including but not limited to the size of the body surface area), a symptom type parameter indicating the severity of the number of symptom onset types (including but not limited to the number of different types of symptoms), and a symptom difference parameter indicating the severity of the difference between the onset symptoms of a single disease (including but not limited to the appearance of scleroderma on the skin: 4 points, the appearance of tissue redness or rash: 1 point, and none: 0 points; the appearance of polyps in the nose: 2 points, the appearance of tissue redness or rash: 1 point, and none: 0 points). The time parameter includes a symptom difference parameter indicating the frequency of symptom onset (including but not limited to the number of different types of symptoms). The patient is provided with at least one of an attack frequency parameter indicating the severity of the attack (including but not limited to, the number of attacks per day or per week) and an attack duration parameter indicating the severity of the duration of the symptom attack (including but not limited to, an attack duration of more than 12 hours and less than 24 hours: 8 points, an attack duration of more than 4 hours and less than 12 hours: 4 points, an attack duration of less than 4 hours: 2 points), and the medication parameters include at least one of a drug dependence parameter indicating the severity of whether the attack needs to be controlled by drugs, a drug dosage parameter indicating the severity of the amount of drugs used during the attack, and a drug dosage parameter indicating the severity of the difference in drug dosage forms used during the attack [including but not limited to, a small amount of oral medication: 2 points, oral medication: 4 points, topical medication: 1 point, simultaneous use of oral and topical medications (regardless of the dosage): 4+1=5 points].

[0021] In step 22, the processing module 12 of the computing device 1 obtains a plurality of corresponding inflammation scores according to the evaluation parameters.

[0022] In step 23, the processing module 12 of the computing device 1 determines whether at least one of the plurality of weighted conditions is triggered according to the evaluation parameters.

[0023] In step 24, when it is determined that the at least one weighting condition is triggered, a weighting process is performed on the obtained inflammation score to obtain a weighted score and the weighted score is used as a quantitative score indicating the degree of inflammation of the first item to be evaluated of the person to be evaluated.

[0024] In step 25, when it is determined that the at least one weighted condition is not triggered, a summing process is performed on the obtained inflammation score to obtain a summed score and the summed score is used as the quantitative score.

[0025] In some specific examples, in step 24, the processing module 12 of the computing device 1 is further configured to perform the following steps: When it is determined that the weighted condition is triggered, determining whether there is at least one evaluation parameter to be deducted for the evaluation parameter that triggers the at least one weighted condition, each evaluation parameter to be deducted meets a corresponding deduction condition; When it is determined that there is at least one evaluation parameter to be deducted, subtracting the inflammation score corresponding to the at least one evaluation parameter to be deducted from the sum of the inflammation scores, and multiplying the sum of the inflammation scores after deduction by at least one preset weight corresponding to triggering the at least one weighted condition to obtain the quantitative score; and When it is determined that there is no at least one evaluation parameter to be deducted, the sum of the inflammation scores is multiplied by at least one preset weight corresponding to the triggering of the at least one weighted condition to obtain the quantitative score.

[0026] In some specific examples, in step 24, the processing module 12 of the computing device 1 is further used to perform the weighted processing by multiplying the inflammation score corresponding to the evaluation parameter that triggers the at least one weighted condition by at least one preset weight corresponding to the at least one weighted condition, and then summing the obtained weighted inflammation score and the inflammation score that does not trigger the weighted condition to obtain the quantitative score.

[0027] According to the present invention, the preset weight may fall within the range of -1000 to +1000.

[0028] Preferably, the processing module 12 of the computing device 1 is further configured to repeatedly execute steps 21 to 24 after step 24, wherein, in the next quantification process, in step 21, the evaluation parameter obtained is related to at least one of the symptoms and medication status of the second item to be evaluated of the person to be evaluated, so as to obtain another quantitative score indicating the degree of inflammation of the second item to be evaluated of the person to be evaluated.

[0029] Preferably, the processing module 12 of the computing device 1 is further configured to, before step 24, execute step 31 to obtain at least one disease indicator related to the disease suffered by the subject to be evaluated, and after obtaining another quantitative score indicating the degree of inflammation of the second subject to be evaluated item, the processing module 12 of the computing device 1 is further configured to execute the following steps: In step 32, a comprehensive evaluation score is obtained based on the quantitative score of the first evaluation item and the other quantitative score of the second evaluation item; and In step 33, the comprehensive assessment score is adjusted according to the at least one disease indicator.

[0030] It is worth mentioning that step 31 can also be executed before step 25 or 33, and is not limited to this.

[0031] According to the present invention, the disease indicators include, but are not limited to: autoimmune disease indicators (e.g., ANA, RF, Anti-ENA Ab, Anti-CCP, Anti-dsDNA Ab, Anti-Cardiolipin IgG / IgM), cancer indicators (e.g., CEA, AFP, CA 125, CA 19-9, CA 15-3, Cyfra21-1, CA72-4, SCC-Ag, EB-VCA IgA, PSA, Beta-HCG), and tissue abnormal proliferation indicators (e.g., gallbladder polyps, uterine fibroids, adenomyosis, thyroid nodules, chocolate cysts).

[0032] For example, consider a patient named A who suffers from severe allergies and suffers from both eczema and allergic rhinitis. Eczema attacks occur daily, covering approximately 50% of the body surface area. Skin growths develop in the affected areas, requiring long-term control with multiple medications (including oral and topical medications). Allergic rhinitis attacks occur approximately once a week, requiring a single oral medication only upon exposure to specific allergens. The patient also has nasal polyps. The results obtained by executing steps 21 and 22 of the method for quantifying the degree of chronic inflammation using computing device 1 are shown in Table 1 below. Table 1 Evaluation parameters Inflammation score (scoring basis) skin nose Symptom pattern parameters 4 (Proliferative tissue appears) 4 (Proliferative tissue appears) Symptom range parameters 5 (The attack area occupies about 50% of the body surface area) 1 (The attack range is approximately equivalent to ≤10% of the body surface area) Symptom Type Parameter 2 (Two different types of symptoms appear) 2 (Two different types of symptoms appear) Seizure frequency parameters 7 (Daily occurrence) 1 (Occurs once a week) Symptom difference parameter 4 (Appearance of hard skin tissue) 2 (Polyps appear) Parameters during seizures 8 (Onset duration is more than 12 hours and less than 24 hours) NULL Drug dependence parameters 2 (Drug dependence) 1 (Partially dependent on drugs) Drug dosage parameters 2 (Two drugs) 1 (a drug) Drug dosage form parameters 5 (including oral medication and topical medication) 4 (Oral medication only) Total 39 16

[0033] Next, weighting is performed according to steps 23 and 24 of the method for quantifying the degree of chronic inflammation as follows: Based on the skin symptom range parameter, it is determined that a weighted condition corresponding to the triggering symptom range exists, and the severity of the symptom range parameter reaches the preset level corresponding to the symptom range. Therefore, an inflammation score of 5 is deducted from the sum, and 5 is used as the preset weight. Furthermore, based on the skin attack frequency parameter, it is determined that a weighted condition corresponding to the triggering attack frequency exists, and the severity of the attack frequency parameter reaches the preset level corresponding to the attack frequency. Therefore, an inflammation score of 7 is deducted from the sum, and 7 is used as the preset weight. Next, based on the skin attack duration parameter, it is determined that a weighted condition corresponding to the triggering attack duration exists, and the severity of the attack duration parameter reaches the preset level corresponding to the attack duration. Therefore, an inflammation score of 8 is deducted from the sum, and 8 is used as the preset weight. Finally, based on the skin drug dependence parameter, drug dosage parameter, and drug dosage form parameter, it is determined that a weighted condition corresponding to the triggering medication condition exists, and 2 is used as the preset weight. The weighting process performed based on this is: (39-5-7-8) × 5 × 7 × 8 × 2 = 10640. Furthermore, the nose evaluation parameters determined that no weighting conditions were triggered. The final total quantitative score is 10640 + 16 = 10656 points.

[0034] Another candidate, B, also suffers from severe allergies, suffering from both eczema and allergic rhinitis. Eczema attacks occur daily, covering approximately 70% of the body surface area. Skin growths develop in the affected areas, requiring long-term use of multiple medications (including oral and topical medications). Allergic rhinitis attacks occur approximately once a week, resolving spontaneously after approximately four hours, requiring medication only after exposure to specific allergens. Furthermore, during a health checkup, an abdominal ultrasound and a gynecological ultrasound revealed gallbladder polyps and uterine fibroids, respectively. Allergen testing reports indicated three Level 5-6 allergens and five Level 3-4 allergens. The results obtained by executing steps 21 and 22 of the method for quantifying the degree of chronic inflammation using the computing device 1 are shown in Table 2 below. Table 2 Evaluation parameters Inflammation score (scoring basis) skin nose Symptom pattern parameters 4 (Proliferative tissue appears) 2 (Redness and swelling of tissue) Symptom range parameters 7 (The attack area covers about 70% of the body surface area) 1 (The attack range is approximately equivalent to ≤10% of the body surface area) Symptom Type Parameter 2 (Two different types of symptoms appear) 1 (Only one type of symptom) Seizure frequency parameters 7 (Daily occurrence) 1 (Occurs once a week) Symptom difference parameter 4 (Appearance of hard skin tissue) 1 (Redness and swelling of tissue) Parameters during seizures 8 (Onset duration is more than 12 hours and less than 24 hours) 2 (Spontaneous resolution within 4 hours) Drug dependence parameters 2 (Drug dependence) 1 (Partially dependent on drugs) Drug dosage parameters 2 (Two drugs) 1 (a drug) Drug dosage form parameters 5 (including oral medication and topical medication) 2 (Only small amounts of oral medication) Total 41 12

[0035] Next, weighting is performed according to steps 23 and 24 of the method for quantifying the degree of chronic inflammation as follows: Based on the skin symptom range parameter, it is determined that the weighted condition corresponding to the triggering symptom range exists, and the severity of the symptom range parameter reaches the preset level corresponding to the symptom range. Therefore, an inflammation score of 7 is deducted from the sum, and 7 is used as the preset weight. Furthermore, based on the skin attack frequency parameter, it is determined that the weighted condition corresponding to the triggering attack frequency exists, and the severity of the attack frequency parameter reaches the preset level corresponding to the attack frequency. Therefore, an inflammation score of 7 is deducted from the sum, and 7 is used as the preset weight. Next, based on the skin attack duration parameter, it is determined that the weighted condition corresponding to the triggering attack duration exists, and the severity of the attack duration parameter reaches the preset level corresponding to the attack duration. Therefore, an inflammation score of 8 is deducted from the sum, and 8 is used as the preset weight. The weighting process performed accordingly is: (41-7-7-8)×7×7×8=7448. Furthermore, based on the nasal assessment parameter, it is determined that no weighted condition exists.

[0036] In addition, weighted scores are added based on the presence of tissue dysplasia indicators (i.e., gallbladder polyps and uterine fibroids). Gallbladder polyps are assigned a score of 9 (4 points for symptom type, 1 point for symptom range, 2 points for symptom type, and 2 points for symptom variance), and uterine fibroids are assigned a score of 12 (4 points for symptom type, 2 points for symptom range, 2 points for symptom type, and 4 points for symptom variance). Parameters without relevant information are not considered. Furthermore, since allergen indicators can also be used as independent factors for physicians' reference, they are considered as a probability effect and recorded as a probability effect multiplier score ranging from 10 to 20 points (referring to IgE levels 1-2, 3-4, and 5-6, which correspond to 1, 10, and 20 points, respectively). However, these scores are not included in the inflammation score. Therefore, the final adjusted quantitative score is 7448 + 12 + 9 + 12 = 7481 points, with a probability effect multiplier score ranging from 10 to 20 points.

[0037] Furthermore, there is an assessed individual, C, who suffers from allergies and only suffers from eczema. Eczema attacks occur approximately twice a week and can be controlled with topical medications. The allergen detection report shows zero allergens at Levels 5-6 and two at Levels 3-4. The results obtained by using computing device 1 to execute steps 22 through 24 of the method for quantifying the degree of chronic inflammation are shown in Table 3 below. Table 3 Evaluation parameters Inflammation score (scoring basis) Symptom pattern parameters 2 (rash appears) Symptom range parameters NULL Symptom Type Parameter 1 (Only one type of symptom) Seizure frequency parameters 2 (2 episodes per week) Symptom difference parameter 1 (rash appears) Parameters during seizures NULL Drug dependence parameters 1 (Partially dependent on drugs) Drug dosage parameters 1 (a drug) Drug dosage form parameters 1 (For external use only) Total 9

[0038] Furthermore, allergen indicators are also considered as a probability effect, and are recorded as a probability effect multiplier score of 10 points (referring to IgE levels 1-2, 3-4, and 5-6, which correspond to 1 point, 10 points, and 20 points, respectively). However, these are not included in the inflammation score. Therefore, the final quantitative score is 9 points, with a probability effect multiplier score of 10 points.

[0039] It is worth mentioning that the actual calculation model will take into account the impact of more different evaluation parameters and the weighting of special conditions to facilitate the overall quantitative evaluation.

[0040] In summary, the method for quantifying the degree of chronic inflammation of the present invention utilizes the computing device 1 to obtain a plurality of corresponding inflammation scores based on a plurality of evaluation parameters related to the symptoms and medication status of the subject to be evaluated. A weighted processing is performed when a weighted triggering condition is determined, and adjustments are made based on the presence or absence of disease indicators. Thus, a quantitative score indicating the degree of inflammation of the subject to be evaluated is obtained, thereby effectively assessing the overall degree of inflammation of the chronic inflammation conditions in different parts of the subject to be evaluated, thereby effectively achieving the purpose of the present invention.

[0041] However, the above is merely an embodiment of the present invention and should not be used to limit the scope of implementation of the present invention. All simple equivalent changes and modifications made according to the scope of the patent application and the content of the patent specification of the present invention are still within the scope of the patent of the present invention.

[0042] 1: Computing device 11: Storage module 12: Processing module 21~25: Steps 31~33: Steps

Claims

1. A method for quantifying the degree of chronic inflammation, suitable for quantifying the degree of inflammation of an item to be evaluated of a person to be evaluated, and executed by a computing device, the method comprising the following steps: (a) obtaining multiple evaluation parameters related to at least one of the symptoms and medication status of the item to be evaluated of the person to be evaluated; (b) obtaining multiple corresponding inflammation scores based on the evaluation parameters; (c) determining whether at least one of multiple weighted conditions is triggered based on the evaluation parameters; (d) when it is determined that at least one weighted condition is triggered, performing a weighted processing on the obtained inflammation score, thereby obtaining a quantitative score indicating the degree of inflammation of the item to be evaluated of the person to be evaluated; (e) repeatedly executing steps (a) to (d), wherein, In the next quantification process, the evaluation parameter obtained by repeatedly performing step (a) is related to at least one of the symptoms and medication status of another item to be evaluated of the person to be evaluated, so as to obtain another quantitative score indicating the degree of inflammation of another item to be evaluated of the person to be evaluated; and (f) a comprehensive evaluation score is obtained based on the quantitative score of the item to be evaluated and the other quantitative score of the other item to be evaluated.

2. The method for quantifying the extent of chronic inflammation as claimed in claim 1, wherein: Step (d) comprises the following sub-steps: (d-1) when it is determined that the weighted condition is triggered, determining whether there is at least one evaluation parameter to be deducted among the evaluation parameters that trigger the at least one weighted condition, and each evaluation parameter to be deducted meets a corresponding deduction condition; (d-2) when it is determined that there is at least one evaluation parameter to be deducted, the inflammation score corresponding to the at least one evaluation parameter to be deducted is subtracted from the sum of the inflammation scores, and the sum of the inflammation scores after deduction is multiplied by at least one preset weight corresponding to the triggering of the at least one weighted condition to obtain the quantitative score; and (d-3) when it is determined that there is no at least one evaluation parameter to be deducted, the sum of the inflammation scores is multiplied by at least one preset weight corresponding to the triggering of the at least one weighted condition to obtain the quantitative score.

3. The method for quantifying the extent of chronic inflammation as claimed in claim 1, wherein: In step (d), the weighted processing is performed by multiplying the inflammation score corresponding to the evaluation parameter that triggers the at least one weighted condition by at least one preset weight corresponding to the at least one weighted condition, and then the weighted inflammation score obtained is summed with the inflammation score that does not trigger the weighted condition to obtain the quantitative score.

4. The method for quantifying the extent of chronic inflammation according to claim 1, wherein: The evaluation parameters include at least one of a plurality of symptom onset parameters related to the symptom onset pattern of the subject to be evaluated, a plurality of time parameters related to the symptom onset time of the subject to be evaluated, and a plurality of medication parameters related to the medication status of the subject to be evaluated.

5. The method for quantifying the extent of chronic inflammation according to claim 4, wherein: The symptom onset parameter includes at least one of a symptom pattern parameter indicating the severity of the symptom onset pattern, a symptom range parameter indicating the severity of the symptom onset site range, a symptom type parameter indicating the severity of the number of symptom onset types, and a symptom difference parameter indicating the severity of the difference in onset symptoms from a single disease. The time parameter includes at least one of an onset frequency parameter indicating the severity of the frequency of symptom onset and an onset duration parameter indicating the severity of the length of the symptom onset. The medication parameter includes at least one of a drug dependence parameter indicating the severity of whether drugs are needed to control the onset, a drug dosage parameter indicating the severity of the amount of drugs used during the onset, and a drug dosage form parameter indicating the severity of the difference in drug dosage forms used during the onset.

6. The method for quantifying the degree of chronic inflammation as described in claim 1 further comprises, before step (d), a step (g), obtaining at least one disease indicator related to the disease suffered by the person to be evaluated, and after step (f), a step (h), adjusting the comprehensive assessment score according to the at least one disease indicator.

7. A computing device for quantifying the degree of chronic inflammation, comprising: a storage module storing weighted conditions of multiple evaluation parameters related to chronic inflammation symptoms and medication status; and a processing module electrically connected to the storage module and used to obtain multiple evaluation parameters related to at least one of the symptoms and medication status of an item to be evaluated of a person to be evaluated, obtain multiple corresponding inflammation scores based on the evaluation parameters, and determine whether at least one of the multiple weighted conditions is triggered based on the evaluation parameters. When it is determined that the at least one weighted condition is triggered, perform a weighted processing on the obtained inflammation score, thereby obtaining a quantitative score indicating the degree of inflammation of the item to be evaluated of the person to be evaluated. The processing module is also used to obtain multiple evaluation parameters related to at least one of the symptoms and medication status of another item to be evaluated of the person to be evaluated, and obtain multiple corresponding inflammation scores according to the evaluation parameters, and determine whether at least one of multiple weighted conditions is triggered according to the evaluation parameters. When it is determined that the at least one weighted condition is triggered, a weighted processing is performed on the obtained inflammation score to obtain another quantitative score indicating the degree of inflammation of another item to be evaluated of the person to be evaluated, and a comprehensive evaluation score is obtained according to the quantitative score of the item to be evaluated and the other quantitative score of the other item to be evaluated.

8. The computing device for quantifying the degree of chronic inflammation according to claim 7, wherein: The processing module is further used to perform the following steps: when it is determined that the weighted condition is triggered, determine whether there is at least one evaluation parameter to be deducted among the evaluation parameters that trigger the at least one weighted condition, and each evaluation parameter to be deducted meets a corresponding deduction condition; when it is determined that there is at least one evaluation parameter to be deducted, subtract the inflammation score corresponding to the at least one evaluation parameter to be deducted from the sum of the inflammation scores, and multiply the sum of the inflammation scores after deduction by at least one preset weight corresponding to the triggering of the at least one weighted condition to obtain the quantitative score; and when it is determined that there is no at least one evaluation parameter to be deducted, multiply the sum of the inflammation scores by at least one preset weight corresponding to the triggering of the at least one weighted condition to obtain the quantitative score.

9. The computing device for quantifying the degree of chronic inflammation according to claim 7, wherein: The processing module is further used to perform the weighted processing by multiplying the inflammation score corresponding to the evaluation parameter that triggers the at least one weighted condition with at least one preset weight corresponding to the at least one weighted condition, and then summing the obtained weighted inflammation score and the inflammation score that does not trigger the weighted condition to obtain the quantitative score.

10. The computing device for quantifying the degree of chronic inflammation according to claim 7, wherein: The evaluation parameters include at least one of a plurality of symptom onset parameters related to the symptom onset pattern of the subject to be evaluated, a plurality of time parameters related to the symptom onset time of the subject to be evaluated, and a plurality of medication parameters related to the medication status of the subject to be evaluated.

11. The computing device for quantifying the degree of chronic inflammation according to claim 10, wherein: The symptom onset parameter includes at least one of a symptom pattern parameter indicating the severity of the symptom onset pattern, a symptom range parameter indicating the severity of the symptom onset site range, a symptom type parameter indicating the severity of the number of symptom onset types, and a symptom difference parameter indicating the severity of the difference in onset symptoms from a single disease. The time parameter includes at least one of an onset frequency parameter indicating the severity of the frequency of symptom onset and an onset duration parameter indicating the severity of the length of the symptom onset. The medication parameter includes at least one of a drug dependence parameter indicating the severity of whether drugs are needed to control the onset, a drug dosage parameter indicating the severity of the amount of drugs used during the onset, and a drug dosage form parameter indicating the severity of the difference in drug dosage forms used during the onset.

12. The computing device for quantifying the degree of chronic inflammation according to claim 7, wherein: The processing module is also used to obtain at least one disease indicator related to the disease suffered by the person to be evaluated, and adjust the comprehensive evaluation score according to the at least one disease indicator.

Images